Moss Genomics

Moss Genomics EBIT per Share

The EBIT per Share of Moss Genomics (MOSS.CN) as of Nov 3, 2026 is -0.01 CAD.

EBIT per Share

-0.01CAD

YoY

144.94%

Last updated:

EBIT per Share of Moss Genomics is 2025 -0.01 CAD. EBIT per Share of Moss Genomics was 2024 -0.00 CAD. It decreases by 144.94% lower compared to the previous year.

The Moss Genomics EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
-0.00 CAD
Jan 1, 2021
-0.00 CAD
Jan 1, 2022
-0.01 CAD
Jan 1, 2023
-0.02 CAD
Jan 1, 2024
-0.00 CAD
Jan 1, 2025
-0.01 CAD
The Moss Genomics EBIT per Share history
YEAREBIT per ShareYoY
-0.01CAD+144.94%
-0.00CAD-81.91%
-0.02CAD+11.45%
-0.01CAD+504.02%
-0.00CAD+13,462.50%
-0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moss Genomics Stock analysis

What does Moss Genomics do? Moss Genomics, Inc. generates revenue through personalized health, anti-aging, and wellness offerings guided by genomic, microbiome, and epigenome data. The company sells products like Gut Health Complete, Gut + Mental Health Complete, and Personalized Probiotic Products. Its services include home collection kits for saliva and fecal samples, genomic and gut microbiome sequencing, and health reports with actionable wellness recommendations. The firm targets consumers seeking tailored health solutions, leveraging AI to analyze DNA and gut microbiome data. Moss Genomics Holdings Inc., its wholly owned subsidiary, supports these offerings. The company operates in San Diego, California, and offers a Multi-Omics Database to improve pharma and biotech drug development. This database integrates genomic, microbiome, and epigenome data from its consumer base, providing value to pharmaceutical and biotech partners. Moss Genomics, Inc. focuses on delivering personalized health insights through its consumer genetic testing segment, which complements its broader health and wellness product line. Moss Genomics, Inc. provides home collection kits for sample gathering, followed by sequencing and analysis to produce health reports. These reports guide users toward personalized wellness strategies, driving customer engagement and repeat purchases. The company’s business model combines direct-to-consumer health products with data-driven insights for the pharmaceutical industry, creating dual revenue streams from both individual consumers and corporate clients. Moss Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moss Genomics stock

EBIT per Share of Moss Genomics is -0.01 CAD in 2025.

On Eulerpool you can find the complete historical development of EBIT per Share Moss Genomics since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Moss Genomics

All Key Metrics — Moss Genomics